REG - Oxford Biomedica PLC - Multi-year supply agreement with BMS

Oxford BioMedicaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260204:nRSD5780Ra&default-theme=true

RNS Number : 5780R  Oxford Biomedica PLC  04 February 2026

 

 

OXB Signs New Multi-Year Commercial Supply Agreement with Bristol Myers Squibb

-     OXB to become commercial manufacturer of lentiviral vectors for
Bristol Myers Squibb (BMS) CAR-T programmes

-     Multi-year agreement with five-year initial term and option to
extend

 

Oxford, UK - 4 February 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, today announces it has expanded its
strategic partnership with Bristol Myers Squibb ("BMS") (NYSE: BMY), signing a
new Commercial Supply Agreement (CSA) for the manufacture and supply of
lentiviral vectors for BMS' CAR-T programmes.

This expanded partnership builds on the existing relationship with Bristol
Myers Squibb, originally announced in March 2020
(https://oxb.com/oxford-biomedica-signs-license-clinical-supply-agreement-with-juno-therapeutics-inc-a-bristol-myers-squibb-company-for-lentivector-platform-for-car-t-and-tcr-t-therapeutics/)
.

Under the new agreement, OXB is expected to commence commercial manufacturing
in 2026, subject to regulatory approval of the relevant CAR-T products.
Manufacturing will take place at OXB's facilities in Oxford, UK, and Durham
NC, US.

The CSA is expected to generate meaningful multi-year revenue and supports the
Company's existing medium-term financial guidance, demonstrating further
successful execution of OXB's focused cell and gene therapy CDMO strategy.

 

Dr Sebastien Ribault, Chief Business Officer of OXB, commented: "The
transition from clinical to commercial manufacturing with BMS marks an
important milestone for both companies. Having supported these potentially
life-saving CAR-T programmes through development, we are confident in their
commercial success and look forward to continuing our partnership with BMS.
This long-term commitment underlines our excellent revenue visibility,
reflects our strong track record, and demonstrates continued successful
execution of our strategy as a leading cell and gene therapy CDMO."

Chris Holt, Vice President, Cell Therapy Vector and External Manufacturing
Operations, Bristol Myers Squibb, added: "OXB has been an excellent
manufacturing partner supporting our CAR-T cell therapy programmes through
clinical development. This expanded agreement reflects our confidence in their
world-class capabilities and proven expertise in delivering high-quality,
commercial-grade viral vectors. As we advance our innovative CAR-T therapies
toward patients, this strategic partnership ensures reliable, scalable
manufacturing capacity to meet commercial demand."

 

-Ends-

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRBLGDDBBGDGLX



            Copyright 2019 Regulatory News Service, all rights reserved